The psychedelic alkaloid ibogaine has anti-addictive properties in both humans and animals
1. Unlike most medications for the treatment of substance use disorders, anecdotal reports …

Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of
depression and related disorders. The ability to promote both structural and functional …

Decreased dendritic spine density in the cortex is a hallmark of several neuropsychiatric
diseases, and the ability to promote cortical neuron growth has been hypothesized to underlie …

Drugs capable of ameliorating symptoms of depression and anxiety while also improving
cognitive function and sociability are highly desirable. Anecdotal reports have suggested that …

Depression and anxiety disorders are debilitating diseases resulting in substantial economic
costs to society. Traditional antidepressants often take weeks to months to positively affect …

Psychedelic compounds have displayed antidepressant potential in both humans and
rodents. Despite their promise, psychedelics can induce undesired effects that pose safety …

Serotonin plays a central role in cognition and is the target of most pharmaceuticals for
psychiatric disorders. Existing drugs have limited efficacy; creation of improved versions will …

Objective: Does early treatment of spasticity with botulinum-toxin (BoNTA), in (hyper)acute
stroke patients without arm-function, reduce contractures and improve function. Design: …

Though relatively obscure, N,N-dimethyltryptamine (DMT) is an important molecule in
psychopharmacology as it is the archetype for all indole-containing serotonergic psychedelics. Its …

Anecdotal reports suggest that the administration of sub-hallucinogenic doses of psychedelic
compounds on a chronic, intermittent schedule – a practice known as psychedelic …